Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Technical Presentation (May 2026)
24 slides from Novo Nordisk A/s Class B's technical presentation, May 7, 2026
Slide 1: Modelling PD Progression To Quantify Long-Term Treatment Effects
Modelling PD Progression To Quantify Long-Term Treatment Effects The Concept of `Time-Saved`: Insights From PPMI and PASADENA Open-Label Extension Benjamin Ribba,1 Tania Nikolcheva,2 Philippe B. Pierrillas,1 Cheikh Diack,1 Annabelle Monnet,2 Benedicte Ricci,1 Matthew May,1 Gennaro Pagano,1,3 Geoffre
Slide 2: Affiliations
Affiliations 1. Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland* 2. Product Development Neurology, F. Hoffmann-La Roche Ltd, Basel, Switzerland 3. University of
Slide 3: Disclosures
Disclosures ▪ Benjamin Ribba, Tania Nikolcheva, Philippe B. Pierrillas,* Cheikh Diack, Annabelle Monnet, Benedicte Ricci, Matthew May, Gennaro Pagano, Geoffrey A. Kerchner and Patrik Brundin: Full-time employees and own shares of F. Hoffmann-La Roche Ltd *Philippe B. Pierrillas affiliation at time o
Slide 4: It's a question of Time
It’s a question of Time People with Parkinson’s are talking about Time “If there was a cure found for Parkinson's now, it would "I'm trying to buy myself as give me back my future” much time as I can, so I don't develop the negative side effects of dopaminergic treatment" "3 months ago I was able to
Slide 5: The `Time Gained` Concept
The `Time Gained` Concept Shifting the efficacy paradigm: From 'Points Change' to 'Time Gained' Time gained Natural history / Placebo Treatment 5
Slide 6: The `Time Gained` Concept
The `Time Gained` Concept Shifting the efficacy paradigm: From 'Points Change' to 'Time Gained' Natural History / Placebo (e.g., MDS-UPDRS Score) Disease severity Worsening Time MDS-UPDRS, Movement Disorder Society-Unified Parkinson's Disease Rating Scale. 6
Slide 7: The `Time Gained` Concept
The `Time Gained` Concept Shifting the efficacy paradigm: From 'Points Change' to 'Time Gained' Natural History / Placebo (e.g., MDS-UPDRS Score) Disease severity Worsening Treatment Time MDS-UPDRS, Movement Disorder Society-Unified Parkinson's Disease Rating Scale. 7
Slide 8: The `Time Gained` Concept
The `Time Gained` Concept Shifting the efficacy paradigm: From 'Points Change' to 'Time Gained' Natural History / Placebo (e.g., MDS-UPDRS Score) Disease severity Worsening Standard metric: (Score difference) Treatment Time MDS-UPDRS, Movement Disorder Society-Unified Parkinson's Disease Rating Scal
Slide 9: The `Time Gained` Concept
The `Time Gained` Concept Shifting the efficacy paradigm: From 'Points Change' to 'Time Gained' Natural History / Placebo (e.g., MDS-UPDRS Score) Disease severity Time gained Worsening Standard metric: (Years of progression avoided) (Score difference) Treatment Time MDS-UPDRS, Movement Disorder Soci
Slide 10: The Challenge: Detecting signal in early-stage PD
The Challenge: Detecting signal in early-stage PD Slow progression rates, symptomatics masking treatment effects, and variability in Parkinson’s journey Slowly progressing Limitations of disease current measurement tools Low signal: Without sensitive ❑ Low rate of change in early quantification, dis
Slide 11: The Feasibility Gap: Why we need modelling
The Feasibility Gap: Why we need modelling Clinical trial simulations suggest standard designs can hardly detect change in function Endpoint selection = patient-relevant outcomes x capacity to detect a response in randomised clinical trials Time (years) to 90% probability of study success Probabilit
Slide 12: Clinician-assessed motor signs as leading indicator
Clinician-assessed motor signs as leading indicator Longitudinal modelling of natural history identifies progression of MDS-UPDRS Part III earlier and faster than Part II Backward extrapolation of MDS-UPDRS Part Modelled PPMI progression III scores supported by PPMI data in the MDS-UPDRS Part III OF
Slide 13: Slowing progression of motor signs could predict functional outcome
Slowing progression of motor signs could predict functional outcome MDS-UPDRS Part III and Part II Time MDS-UPDRS, Movement Disorder Society-Unified Parkinson's Disease Rating Scale; OLE, open-label extension; PPMI, Parkinson’s Progression Markers Initiative; pt, patient. 13
Slide 14: Slowing progression of motor signs could predict functional outcome
Slowing progression of motor signs could predict functional outcome MDS-UPDRS Part III: ~3pts/year Trial Trial MDS-UPDRS Part III and Part II start stop MDS-UPDRS Part II: ~1pt/year Time MDS-UPDRS, Movement Disorder Society-Unified Parkinson's Disease Rating Scale; OLE, open-label extension; PPMI, P
Slide 15: Slowing progression of motor signs could predict functional outcome
Slowing progression of motor signs could predict functional outcome MDS-UPDRS Part III: ~3pts/year Trial Trial MDS-UPDRS Part III and Part II start stop MDS-UPDRS Part II: ~1pt/year Time needed to observe the Time same magnitude of effect MDS-UPDRS, Movement Disorder Society-Unified Parkinson's Dise
Slide 16: Slowing progression of motor signs could predict functional outcome
Slowing progression of motor signs could predict functional outcome MDS-UPDRS Part III: ~3pts/year Trial Trial MDS-UPDRS Part III and Part II start stop MDS-UPDRS Part II: ~1pt/year Time needed to observe the Time same magnitude of effect MDS-UPDRS, Movement Disorder Society-Unified Parkinson's Dise
Slide 17: Slowing progression of motor signs could predict functional outcome
Slowing progression of motor signs could predict functional outcome MDS-UPDRS Part III: ~3pts/year Comparison to PASADENA OLE data with PPMI- Trial Trial based model predictions supports the hypothesis that effect on signs precedes effect on symptoms MDS-UPDRS Part III and Part II start stop MDS-UPD
Slide 18: Constructing a virtual comparator
Constructing a virtual comparator PASADENA and PPMI virtual Model accurately predicts Placebo 3 comparator design 60 PPMI-based model predictions DB placebo- Non-placebo controlled dose Open-label extension period treatment comparison (up to 5 years) PASADENA data (placebo arm) (52 weeks) (52 weeks)
Slide 19: Prasinezumab delays progression by ~2 years over years of treatment
Prasinezumab delays progression by ~2 years over 5 years of treatment Consistent ~2 years of ‘Time Gained’ across motor and functional domains Disease modelling suggests an average of Slower progression compresses Sustained Effect of ~2 years saved over 5 years of the vertical signal but the time sa
Slide 20: Potential for additional 'time gained' beyond years
Potential for additional ‘time gained’ beyond 2 years Interpreting the structural impact of 'Missing Not At Random' attrition Withdrawals increase at Year 5 in PPMI MDS-UPDRS Part II MDS-UPDRS Part III OFF 6 Withdrawal % 5 4 3 2 0 1 2 3 4 5 6 7 8 Year of last measurement MDS-UPDRS, Movement Disorder
Slide 21: Potential for gaining even more time beyond years
Potential for gaining even more time beyond 2 years Interpreting the structural impact of 'Missing Not At Random' attrition Withdrawals increase at Year 5 in PPMI Baseline characteristics: All participants vs withdrawn in PPMI MDS-UPDRS Part II All Withdrawn MDS-UPDRS Part III OFF participants parti
Slide 22: Potential for gaining even more time beyond years
Potential for gaining even more time beyond 2 years Interpreting the structural impact of 'Missing Not At Random' attrition Observation: PPMI Attrition Withdrawals increase at Year 5 in PPMI Baseline characteristics: All participants vs withdrawn Withdrawals increase at Year 5 in PPMI MDS-UPDRS Part
Slide 23: Summary
Summary Quantifying long-term value through modelling ❏ Modelling establishes Motor Signs (MDS-UPDRS Part III OFF) as a robust “Leading Indicator” for future functional decline (MDS-UPDRS Part II) ❏ This metric translates complex clinical data into tangible measures ❏ Prasinezumab treatment resulted
Slide 24: Acknowledgements
Acknowledgements We thank all the study participants and their families, and investigators and site staff, for their time and commitment to the prasinezumab clinical development programme https://go.roche.link/xxlh74